Lifecore Biomedical (NASDAQ:LFCR) Posts Earnings Results, Misses Estimates By $0.05 EPS

Lifecore Biomedical (NASDAQ:LFCR) released its quarterly earnings data on Monday. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.05), Zacks reports. The company had revenue of $35.75 million during the quarter, compared to analyst estimates of $35.31 million. Lifecore Biomedical had a negative net margin of 23.08% and a negative return on equity of 1,211.09%.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• The company reported strong recent results with Q4 2025 revenues of $35.7 million (+10%) and a seven‑month transition period revenue of $75.5 million (+20%)
• Lifecore highlighted major operational wins supporting a 2027 inflection—successful qualification of its five‑head isolator filler for Europe/Asia and HA qualification for Japan position it to support a planned >2x increase in aseptic fill demand from its largest customer.
• The company pushed expected launch timelines for its late‑stage pipeline from 2026–2029 to 2027–2030, citing customer development changes and financing issues, which delays potential commercialization revenue.
• Management has materially reduced operating expenses, improved liquidity to approximately $39 million (including ~$17.5M cash), paid down ~$20M of debt, and expects >$10M free cash flow in 2026, supporting financial stability.
• 2026 guidance: revenue of $120–125 million, net loss of $28.9–33.4 million, and adjusted EBITDA of $20.5–25 million, with the outlook explicitly contingent on customer supply‑chain shifts, inventory timing and a delayed commercial launch.

Lifecore Biomedical Price Performance

LFCR opened at $4.36 on Wednesday. The firm has a market cap of $163.37 million, a P/E ratio of -4.45 and a beta of 0.62. The company has a debt-to-equity ratio of 113.76, a quick ratio of 1.67 and a current ratio of 2.80. The business has a 50 day moving average price of $7.47 and a 200 day moving average price of $7.46. Lifecore Biomedical has a twelve month low of $4.09 and a twelve month high of $8.98.

Institutional Trading of Lifecore Biomedical

Several large investors have recently modified their holdings of LFCR. Invesco Ltd. acquired a new position in Lifecore Biomedical during the 2nd quarter worth $3,081,000. Squarepoint Ops LLC increased its stake in shares of Lifecore Biomedical by 385.9% in the third quarter. Squarepoint Ops LLC now owns 150,909 shares of the company’s stock worth $1,111,000 after purchasing an additional 119,851 shares during the period. Millennium Management LLC lifted its position in shares of Lifecore Biomedical by 86.2% during the 4th quarter. Millennium Management LLC now owns 251,705 shares of the company’s stock worth $2,059,000 after purchasing an additional 116,500 shares during the last quarter. Quinn Opportunity Partners LLC boosted its stake in Lifecore Biomedical by 31.5% during the 4th quarter. Quinn Opportunity Partners LLC now owns 242,670 shares of the company’s stock valued at $1,985,000 after purchasing an additional 58,189 shares during the period. Finally, State Street Corp boosted its stake in Lifecore Biomedical by 8.5% during the 4th quarter. State Street Corp now owns 585,386 shares of the company’s stock valued at $4,788,000 after purchasing an additional 46,102 shares during the period. 83.36% of the stock is owned by institutional investors.

Trending Headlines about Lifecore Biomedical

Here are the key news stories impacting Lifecore Biomedical this week:

• Positive Sentiment: Barrington Research upgraded Lifecore from “market perform” to “outperform” and set a $5.50 price target (~26% upside vs. the current price), which can attract buyers and help support the stock. Barrington Research Upgrade
• Positive Sentiment: Company press release and filings show recorded fourth-quarter revenues of $35.7M and transition-period revenues of $75.5M, plus multiple new programs signed (including commercial site transfers) and initiatives to improve margins — fundamentals that support medium-term growth expectations. Company Press Release
• Positive Sentiment: Management is targeting a ~12% revenue CAGR through 2029, signaling an organized growth plan and setting investor expectations for sustained topline expansion (though execution risk remains). Seeking Alpha: Growth Target
• Neutral Sentiment: Q4 results were mixed: revenue slightly beat consensus ($35.75M vs. $35.31M) but EPS missed (loss of $0.16 vs. consensus -$0.11). Investors will parse whether margin improvements and new program wins offset near-term profitability weakness. Conference call transcript, press release and slide deck available for detail. Earnings Details & Call
• Negative Sentiment: A shareholder firm (Johnson Fistel) announced an investigation into potential claims involving Lifecore executives, which introduces legal risk and could pressure sentiment until resolved. Shareholder Investigation

Analyst Upgrades and Downgrades

LFCR has been the subject of several recent research reports. Zacks Research raised Lifecore Biomedical to a “hold” rating in a research note on Thursday, January 1st. Barrington Research raised shares of Lifecore Biomedical from a “market perform” rating to an “outperform” rating and set a $5.50 target price for the company in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.50.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.

Featured Stories

• Five stocks we like better than Lifecore Biomedical